Anke van den Berg
prof. dr.
I work as a clinical molecular biologist in the department of Pathology. In this function I supervise and implement advanced molecular diagnostic techniques. Within my research line, I focus on the molecular pathogenesis of B-cell Hodgkin and non-Hodgkin lymphoma. The specific fields of interest are genomic aberrations, genetic susceptibility, and the role of small and long noncoding RNAs. I have several international collaborations and am PI and co-PI in various projects.
Generation of miRNA sponge constructs
Published in: Methods
Access to document
10.1016/j.ymeth.2012.07.019
MicroRNA (miRNA) sponges are RNA molecules with repeated miRNA antisense sequences that can sequester miRNAs from their endogenous targets and thus serve as a decoy. Stably expressed miRNA sponges are especially valuable for long-term loss-of-function studies and can be used in vitro and in vivo. We describe here a straightforward method to generate retroviral miRNA sponge constructs using a single directional ligation reaction. This approach allows generation of sponges containing more than 20 miRNA binding sites. We provide a basis for the design of the sponge constructs with...
Joost Kluiver, Izabella Slezak-Prochazka, Katarzyna Smigielska-Czepiel, Nancy Halsema, Bart-Jan Kroesen, Anke van den Berg
HLA Associations in Classical Hodgkin Lymphoma: EBV Status Matters
Published in: PLoS ONE
Access to document
10.1371/journal.pone.0039986
document
The pathogenesis of classical Hodgkin lymphoma (cHL) involves environmental and genetic factors. To explore the role of the human leukocyte antigen (HLA) genes, we performed a case-control genotyping study in 338 Dutch cHL patients using a PCR-based sequence-specific oligonucleotide probe (SSOP) hybridization approach. The allele frequencies were compared to HLA typings of more than 6,000 controls. The age of the cHL patients varied between 13 and 81 years with a median of 35 years. Nodular sclerosis subtype was the most common subtype (87%) and EBV was detected in...
Xin Huang, Kushi Kushekhar, Ilja Nolte, Wierd Kooistra, Lydia Visser, Ilby Bouwman, Niels Kouprie, Rianne Veenstra, Gustaaf van Imhoff, Bianca Olver, Richard S. Houlston, Sibrand Poppema, Arjan Diepstra, Bouke Hepkema, Anke van den Berg
Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin’s lymphoma
Published in: Haematologica
Access to document
10.3324/haematol.2011.056101
document
BACKGROUND: The c-Met signaling pathway regulates a variety of biological processes, including proliferation, survival and migration. Deregulated c-Met activation has been implicated in the pathogenesis and prognosis of many human malignancies. We studied the function and prognostic significance of c-Met and hepatocyte growth factor protein expression in patients with classical Hodgkin’s lymphoma. DESIGN AND METHODS: Expression of c-Met and its ligand, hepatocyte growth factor, were determined by immunohistochemistry. Prognostic values were defined in cohorts of German and Dutch patients with classical Hodgkin’s lymphoma. Functional studies were performed on...
Chuanhui Xu, Wouter Plattel, Anke van den Berg, Nele Ruether, Xin Huang, Miao Wang, Debora de Jong, Hans Vos, Gustaaf van Imhoff, Andreas Viardot, Peter Moeller, Sibrand Poppema, Arjan Diepstra, Lydia Visser
Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin’s lymphoma
Published in: Haematologica
Access to document
10.3324/haematol.2011.053199
document
BACKGROUND: Plasma thymus and activation-regulated chemokine is a potential biomarker for classical Hodgkin’s lymphoma. To define its value as a marker to monitor treatment response, we correlated serial plasma thymus and activation-regulated chemokine levels with clinical response in newly diagnosed and relapsed classical Hodgkin’s lymphoma patients. DESIGN AND METHODS: Plasma was collected from 60 (39 early stage and 21 advanced stage) newly diagnosed classical Hodgkin’s lymphoma patients before, during, and after treatment, and from 12 relapsed patients before and after treatment. Plasma thymus and activation-regulated chemokine levels were...
Wouter J. Plattel, Anke van den Berg, Lydia Visser, Anne-Marijn van der Graaf, Jan Pruim, Hans Vos, Bouke Hepkema, Arjan Diepstra, Gustaaf W. van Imhoff
HLA-A*02:07 Is a Protective Allele for EBV Negative and a Susceptibility Allele for EBV Positive Classical Hodgkin Lymphoma in China
Published in: PLoS ONE
Access to document
10.1371/journal.pone.0031865
document
HLA-A2 protects from EBV+ classical Hodgkin lymphoma (cHL) in Western Europe, but it is unknown whether this protective effect also exists in the Chinese population. We investigated the association of HLA-A2 and specific common and well documented HLA-A2 subtypes with EBV stratified cHL patients (n = 161) from the northern part of China. Quantitative-PCR and sequence-based subtyping was performed to identify HLA-A2 positive samples and their subtypes. 67 (42%) of the cHL patients were EBV+. There were no significant differences in percentages of HLA-A2 positivity between cHL and...
Xin Huang, Bouke Hepkema, Ilja Nolte, Kushi Kushekhar, Theo Jongsma, Rianne Veenstra, Sibrand Poppema, Zifen Gao, Lydia Visser, Arjan Diepstra, Anke van den Berg